Clinical data
ATC code None
CAS Number 1159600-41-5
PubChem (CID) 57336276
ChemSpider 34500832
Chemical and physical data
Formula C21H20FN3O5S
Molar mass 445.464003 g/mol
3D model (Jmol) Interactive image

Basmisanil (INN) (developmental code names RG-1662, RO5186582) is a highly selective inverse agonist/negative allosteric modulator of α5 subunit-containing GABAA receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome.[1][2][3] As of August 2015, it is in phase II clinical trials for this indication.[4]

See also


  1. Froestl W, Muhs A, Pfeifer A (2012). "Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors". J. Alzheimers Dis. 32 (4): 793–887. doi:10.3233/JAD-2012-121186. PMID 22886028.
  2. Hurley, Dan (2013). "Investigators Silence Trisomy 21 Chromosome in Human Down Syndrome Cells". Neurology Today. 13 (17): 14–15. doi:10.1097/01.NT.0000434604.55014.fd. ISSN 1533-7006.
  3. Rudolph, Uwe; Jensen, Henrik Sindal; Nichol, Kathryn; Lee, Deborah; Ebert, Bjarke (2014). "Clobazam and Its Active Metabolite N-desmethylclobazam Display Significantly Greater Affinities for α2- versus α1-GABAA–Receptor Complexes". PLoS ONE. 9 (2): e88456. doi:10.1371/journal.pone.0088456. ISSN 1932-6203.
  4. AdisInsight. "Basmisanil". Retrieved 2015-06-10.

External links

This article is issued from Wikipedia - version of the 10/28/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.